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Abstract 
This study examined how perception of people with ADHD is influenced by observation of 
ADHD symptoms and knowledge of prescribed stimulant medication use (PSMU). Ninety-
two undergraduates individually watched a video of a target person either not showing 
symptoms nor indicating PSMU, not showing symptoms but indicating PSMU, showing 
symptoms but not indicating PSMU, or both showing symptoms and indicating PSMU. 
Participants then completed questionnaire measures of their degree of liking of and desire for 
affiliation with the target, as well as level of knowledge about ADHD and their perception of 
PSMU acceptability. Results indicated that depictions of symptoms were perceived more 
negatively than normal behavior, and that symptoms had a larger effect than PSMU on 
stigma. In fact, PSMU did not seem to significantly influence opinions of the targets, as a 
combination of symptoms and PSMU did not result in significantly lower scores, as 
compared to a depiction of symptoms alone. Generally,  this provides evidence that the 
symptoms of ADHD are the primary driver of negative stigma, not PMSU. 
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Is it the Medication or the Symptoms? Examining Perceptions of ADHD in College Students 
   Attention-Deficit/Hyperactivity Disorder (ADHD) is a relatively common 
neurodevelopmental disorder that emerges in early childhood.  In general, those with ADHD 
can struggle with impulse control, hyperactivity (often seen as restlessness in adults), and 
inattention. In order to be diagnosed, a patient must have shown multiple symptoms prior to 
the age of 12, and these symptoms must impact the person in multiple areas of life. These can 
be, but are not limited to, school, work, and social functioning (American Psychiatric 
Association, APA, 2013). There are three types of ADHD. Predominantly inattentive 
presentation is characterized by difficulty in sustaining attention in general, forgetfulness, 
disorganization, distractedness or in dedicating attention to small details, and an avoidance of 
tasks that require strong mental focus. There is also predominantly hyperactive/impulsive 
presentation, which displays itself through frequent fidgeting, difficulty staying in an 
expected place or waiting for one’s turn, speaking excessively and interrupting others 
frequently, or feeling “driven by a motor,” in which case relaxing and quietly doing leisure 
activities is impaired. In adults with ADHD, these symptoms often manifest less as 
hyperactivity and more as restlessness. Finally, there is Combined presentation, which 
encompasses both clusters of symptoms (APA, 2013).  
The concept of ADHD as an enduring issue for adults is relatively new. Until the past 
few decades, ADHD was thought of as a disorder restricted to childhood and perhaps 
adolescence, but now there is a growing body of literature about the effects of adult ADHD 
(Zalsman & Shilton, 2016). In adults, the most common of the three presentations is 
predominant inattention, accounting for approximately 47% of cases. It is hypothesized that 
this may be due to an increased necessity of attention as one ages, which can lead to the 
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symptoms becoming more obvious and the subsequent impairment more severe (Willcutt, 
2012). 
ADHD is fairly common, with a worldwide prevalence rate of roughly 5.29% 
(Polanczyk et al., 2007). In adults, the incidence is more evenly distributed between the 
sexes, whereas in children and adolescents there is a two to three times higher rate of 
diagnosis in males than females (Zalsman & Shilton, 2016). ADHD diagnosis is also 
distributed differently according to location. ADHD should have roughly the same 
prevalence of existence throughout the world, with a heritability of around 80%, but rates of 
diagnosis vary. For example, the United States and Europe have similar rates, but are higher 
than other parts of the world, such as Africa or the Middle East. It is generally believed that 
cultural and/or the environment in which one is raised contributes strongly to whether or not 
one is formally diagnosed, but perhaps not to whether one actually has the disorder 
(Polanczyk, de Lima, Horta, Biederman, & Rohde, 2007). 
Though one of the requirements for diagnosis is that symptoms cannot be better 
explained by another disorder (American Psychological Association, 2013), ADHD is very 
commonly comorbid with another mental disorder. Reale et al. (2017) found that 66% of 
children and adolescents with ADHD have at least one comorbidity. Most common among 
these were learning disorders (56%), sleep disorders (23%), Oppositional Defiant Disorder 
(20%), and anxiety disorders (12%). There is much more research regarding comorbidity in 
children, but research suggests these issues continue into adulthood. Adults with ADHD are 
more likely to have experienced oppositional, conduct, and substance use and abuse disorders 
than their non-diagnosed peers (Murphy & Barkley, 1996).  
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Domains of Impairment Associated with ADHD 
ADHD is probably most associated with impairments in the academic domain. In 
adolescence and childhood, inattentive symptoms (e.g., difficulty organizing and avoiding 
doing tasks which require sustained mental effort) seem to be particularly troubling for those 
with ADHD, contributing to struggles with learning, lower grades on average, and worsened 
performance despite normative intelligence. Hyperactive/impulsive symptoms can also 
contribute to hindered academic performance. Teacher reports indicate that a student’s 
hyperactive/impulsive symptoms can negatively influence their relationships in the 
classroom (Zoromski, Owens, Evans, & Brady, 2015). This may lead to even more difficulty 
in academic functioning. 
It can be difficult to quantify this impairment in college students, as not as many 
people with ADHD attend and let alone graduate from college in relation to those without the 
disorder (Gray, Fettes, Woltering, Mawjee, & Tannock, 2016). However, there is some 
research that helps illustrate ADHD-related academic impairments in college settings. Gray 
et al. (2016) found that despite performing as well as the “average” non-ADHD peer on tests 
of intelligence and working memory, people with ADHD do not earn equivalent grades in 
college. Beyond the expected issues detailed above, the study also found that people with 
ADHD tended to face impairments in executive functioning skills in their daily lives. Some 
of these are not included in the DSM-5 code specifically but seem to have a hindering effect 
on academic performance. These include problems with thinking through problems 
thoroughly, impairment in time management, sluggish cognitive tempo, and psychological 
distress related to their ADHD symptoms (Gray et al., 2016). 
Impairment in vocational functioning is another issue that many adults with ADHD 
face. This can be reflected in socioeconomic status, as adults with ADHD tend to have lower 
ADHD MEDICATION AND SYMPTOM PERCEPTION 
7 
outcomes in this regard than their non-diagnosed peers (Agnew-Blais et al., 2018). It may be 
most apparent, though, in actual work performance. Through a simulated work study, 
Biederman et al. (2005) found that there were significantly more deficits faced in the 
simulation by those with ADHD than those without, including lower mathematical 
competency, decreased inhibition, and behavioral issues such as lowered ability to stay still, 
begin and complete a task, and pay attention. These problematic behaviors were observed to 
prevent those with ADHD from performing as well as the non-ADHD participants. The 
researchers also indicated that these issues are especially problematic in the current work 
world, which is increasingly geared toward teamwork and cooperative effort (Biederman et 
al., 2005). 
Even in samples of adults whose ADHD is treated with medication, impairment is 
still apparent. A 2010 study (Safren, Sprich, Cooper-Vince, Knouse, & Lerner, 2010) found 
that life impairment appears to be greatest in the workplace, followed by interpersonal 
deficits. All of the 105 participants sampled by Safren et al. reported experiencing at least 
some impairment in the work setting, and analyses indicated that inattentive symptoms (e.g., 
simple mistakes due to forgetfulness, disorganization, distractedness) appear to be the most 
hindering in this regard.  
 ADHD is associated with other impairments as well. For example, significantly more 
people with ADHD than without have had their driver’s license suspended (Murphy & 
Barkley, 1996). In addition, impairments in inhibition can relate to struggles with substance 
abuse.  At the age of eighteen, people with ADHD have a higher risk than those that do not 
of being dependent marijuana and a higher risk of engaging in the usage of illicit drugs. In 
addition, addiction to nicotine and alcohol is greater in those with ADHD (Agnew-Blais et 
al., 2018)  
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Social impairment. Another of the domains that people with ADHD suffer 
impairment in is that of social interaction. This is apparent in romantic relationships – for 
example, it is more likely that someone with ADHD will have multiple marriages than 
someone who does not (Murphy & Barkley, 1996) – but also in other relationships and in 
everyday social interactions. 
 Greene et al. (2001) found that, regardless of gender, people with ADHD have 
deficits in interpersonal skills that are in both specific types of interactions (e.g., at school, 
with family, with peers) and more broadly in their general interactions. Further, Green et al. 
found that people with ADHD tend to not score as high as others on general social 
competency, indicating an impairment in both social behavior and comprehension. 
 The severity of core ADHD symptoms seems to contribute to social and relational 
issues. Compared to peers with less severe symptoms, those with elevated symptoms report 
greater difficulties in dealing with interpersonal conflict and providing others with emotional 
support. In addition, having more severe symptoms is associated with a decrease in quality in 
friendships (McKee, 2014). 
 It has been hypothesized that difficulty in managing emotions and deficits in 
emotional knowledge may contribute to social maladjustment in those with ADHD 
(Zoromski et al., 2015; Bunford, Evans, & Langberg, 2018). More specifically, Bunford et al. 
(2018) found that there were three aspects of emotional dysregulation that were especially 
predictive of social impairment in this population. These included high excitability or 
impatience, difficulty in controlling behavior when faced with powerful emotions, and a 
relatively slow return to emotional baseline (i.e., lack of emotional flexibility). 
The symptoms that characterize ADHD may well contribute to negative outcomes in 
social interactions. Masuch, Bea, Alm, Deibler, and Sobanski (2018) note that the display of 
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core symptoms that define ADHD can be seen by others in social contexts as immaturity, a 
lack of interest in others, weakness of character, unpredictability, rudeness, and unreliability. 
In addition, Sacchetti & Lefler (2014) note that severity of symptoms is positively associated 
with both social impairment and levels of state and trait anger. Emotions that are poorly 
managed, like anger, are perceived by others and can be off-putting in social situations. 
Given the frequency and intensity of negative social interactions, it is perhaps expected that 
others tend to perceive those with ADHD rather unfavorably, which increases the potential 
likelihood of negative social stigma. 
Stigma in Mental Illness 
Mental illness has often been conceptualized as a double-bind. On the one hand, the 
symptoms of mental illness directly cause distress and impairment. On the other hand, social 
stereotypes of mental illness are often inaccurate and negative in nature, and lead to stigma 
against those struggling with psychological disorders (Rusch, Angermeyer, & Corrigan, 
2005), which also has negative consequences.  
Stigma can be understood as a widely-held set of beliefs and stereotypes that 
contribute to a stigmatized individual’s feeling or experience of societal devaluation due to 
an attribute or group membership. Stigmatic beliefs are often not an accurate representation 
of the person/group (Bell, Long, Garvan, & Bussing, 2011). Within stigma, several social 
dynamics occur, including (a) the labeling of a group, (b) believing and/or perpetuating 
negative stereotypes about the group (e.g., they are weak of mind or character, are dangerous 
to others, are incompetent; Rusch et al., 2005), (c) the subsequent loss of status for members 
of that group, (d) discrimination against members, and (e) attempts by stigmatized and non-
stigmatized individuals to distance themselves from that group (Link & Phelan, 2001). 
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There are two types of stigma: Public and self. Public stigma is manifested in outward 
behavior toward a stigmatized group (e.g., those with mental illness) that reflects the 
commonly held negative beliefs. Self-stigma entails the internalization of those stigmatizing 
beliefs by the people that are being stigmatized (Rusch et al., 2005), which creates negative 
self-regard that can exacerbate symptoms and impairment esteem (Link, Struening, Neese-
Todd, Asmussen, & Phelen, 2001).  
 Unfortunately, the general public endorses negative beliefs about the mentally ill, 
such as those described above (Rusch et al., 2005). In addition to affecting a person’s self-
regard, stigma can reduce the number of opportunities a person may have. For example, 
stigma has been shown to impact the likelihood of those with mental illness to be hired for a 
position or be accepted as a tenant (Rusch et al., 2005). Concerningly, there is a large body of 
evidence that supports that both public and self-stigma reduces the likelihood that those with 
psychological disorders will seek medical or psychological help for their condition (Clement 
et al., 2015), perhaps due to the widely held public perception that mental illness is the 
responsibility or fault of the person (Rusch et al., 2005) and a subsequent anticipation of 
blame or confrontation. 
Stigma in ADHD 
The research on stigma of psychological disorders is centered primarily on 
schizophrenia and depression, with sparse research regarding the stigmatization of adults 
with ADHD (Masuch et al., 2018). While there are some experimental investigations into 
attitudes toward those with ADHD, there is no national or international survey data to 
provide a baseline of general social acceptance of and prejudice against the disorder 
(Lebowitz, 2016).  
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The symptoms of ADHD are experienced by others through interaction with or 
observation of the affected person. It has been shown that this experience can lead to the 
observer decreasing their amount of interaction with the person with ADHD, increasing their 
social distance from them (Canu, Newman, Morrow, & Pope, 2008). In fact, the most 
prevalent form of stigma displayed toward those with ADHD is a high desire for social 
distance, resulting in reduced social interaction with those with ADHD—in essence, 
ostracism (Lebowitz, 2016; Canu et al., 2008). It has also been shown that situations that 
involve teamwork (e.g. those involved in academic or other work) are ones in which stigma 
toward those with ADHD appears more consistently, perhaps due to reluctance to forge 
social relationships or to rely on another who is perceived negatively (Canu et al., 2008).  
Desire for social distance is not the only manifestation of stigma often seen with 
ADHD. A 2005 study by Paulson et al. examined perceptions of ADHD, depression, and 
social anxiety in relation to “normal” behavior via videos that displayed aspects of each. 
Hostile mood was observed by the researchers more in reaction to ADHD than to the other 
abnormal videos, and ADHD elicited greater rejection than the control. In other words, 
behavior that is consistent with ADHD symptoms can result in greater hostility and rejection 
from peers than does normal behavior, lending to the idea that ADHD symptoms are 
stigmatized. 
It is important to note that ADHD stigmatization is not limited to children and 
adolescents, but occurs in adults as well (Lebowitz, 2016). This seems somewhat illogical, as 
it might be expected that the public would recognize that adults with ADHD may have the 
necessary life experience to adequately manage their symptoms. Unfortunately, stigma is 
readily apparent to those with the disorder. In a 2018 study, Masuch and colleagues found 
that 88.5% of adults with ADHD expected to face discrimination for having the disorder in 
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everyday life, and 69.3% perceived public stigma against them (Masuch et al., 2018). This 
stigma may be implicit or explicit (O’Driscoll, Heary, Hennessy, & McKeague, 2012). Either 
way, for adults with ADHD, the perception and subsequent subjective interpretation of public 
stigma can increase ADHD-related social dysfunction adding to the burden of the disorder 
itself (Masuch et al., 2018). 
Stigma toward Use of Psychiatric Medication 
Stimulant medications, such as amphetamines and methylphenidate, have been 
available for a long time. A few (e.g., Ritalin), were introduced to the market beginning as 
early as the 1950s, making them some of the first psychiatric medications to be widely 
available (Frank & Glied, 2006). Stimulant medications are typically the first method used to 
treat ADHD. They have been shown to be significantly more effective in reducing unwanted 
symptoms of ADHD, as compared to most non-stimulant medications (e.g., NSRIs, SSRIs, 
tricyclic antidepressants). Despite this, there are a multitude of potential negative side effects 
associated with their use that might negatively predispose people to them. Some of these are 
emotional, like personality changes, increased anxiety, and irritability. Physical side effects 
are common as well, such as difficulty sleeping, diminished appetite, tics, stomachaches and 
headaches, and increased heartrate and blood pressure (National Institute of Mental Health, 
2019). While there are non-stimulant medications designed for ADHD (e.g., Strattera), this 
study examines stimulant medication exclusively because they are typically the most widely-
known treatment for the disorder. 
There is virtually no research in regards to stigma against ADHD medication use, 
specifically. There is, however, some research regarding other psychiatric medication. For 
example, antidepressant use, one of the most widely used forms of medication therapy, is 
often stigmatized; therefore, so are those that use them. The stigma seems to be related to the 
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perception that the user is emotionally weak and unable to handle problems. It also appears to 
stem from a lack of belief in the therapeutic ability of antidepressants (Castaldelli-Maia et al., 
2011). 
 What little research is available points to the influence of misinformation regarding 
stimulant medications. Scuttio (2015) found that more accurate knowledge regarding the 
stimulant medications is associated with more positive attitudes about their use. There are 
many misunderstandings regarding stimulant medication for use in treating ADHD, but 
perhaps the most noted is the idea that these medications directly or indirectly result in 
substance abuse later in life, or that patients may become “addicted” to them. When one does 
not believe stimulant medications result in substance abuse or addiction, Scuttio (2015) 
determined that there were fewer negative responses to taking stimulant medication. 
 Worth considering is the idea that stigma toward ADHD could come indirectly from 
knowledge of medication usage, alone, through the medication’s implicit association with 
ADHD. In a 2008 study by Canu et al., it was found that people with ADHD are subject to 
stigma even when the disorder was only signaled with its diagnostic label. College students 
rated their peers with ADHD more negatively than those without, and even appraised them 
more negatively than peers with minor chronic medical issues. This points to the idea that 
simply knowing one has ADHD results in a less favorable view of that person, even when the 
appraiser does not see the target’s symptoms. In sum, if it is known that someone takes 
prescribed stimulant medication, it may result in stigmatization. 
Current Study 
 The current study will evaluate college students’ relative perceptions and acceptance 
of an individual that either shows ADHD symptoms and/or are known to be taking prescribed 
stimulant medication for ADHD, versus an individual with no such indications (i.e., control).  
ADHD MEDICATION AND SYMPTOM PERCEPTION 
14 
 Stigma toward the individuals who depict ADHD symptoms and/or stimulant 
medication use will be measured by two dependent variables: desire for affiliation (DFA) and 
how much the individual is liked (degree of liking, or DOL). Comparison of scores on these 
variables for the ADHD symptoms and/or medication targets will be compared to those of a 
control individual.  
 Based on the literature reviewed above, it is hypothesized that the individuals who 
depict ADHD behaviors will be perceived less positively than those that do not, reflected by 
lower DFA and DOL scores. It is also expected that individuals who indicate prescribed 
stimulant medication use (PSMU) will be perceived less positively than those who do not. 
Further, it is hypothesized that the display of symptoms alone will be perceived more 
negatively than the mention of medication alone. Finally, it is specifically anticipated that the 
individual who displays ADHD behaviors and mentions PSMU will be perceived more 
negatively than any other target.  
 Method 
Participants 
 A sample of 92 undergraduates was recruited through the psychology research 
participant pool at Appalachian State University, all of whom received class credit for their 
participation. All were age 18 or older (M[SD] = 19.61 (1.56) years) and did not have a 
physical disability or impairment that would hinder their ability to complete the procedure. 
Many were first-year students (45.7%; 26.1% second-year, 16.3% third-year, 12% fourth-or-
higher-year). The participants tended to be female (82.6%), heterosexual (91.3), and 
Caucasian (90.2%). Further demographic detail can be noted in Table 1. 
 
 
ADHD MEDICATION AND SYMPTOM PERCEPTION 
15 
Measures 
Video Vignettes. Participants were randomly assigned to view one of four video 
vignettes. All videos featured the same actor answering the same nine general personal 
information questions (e.g., “What do you like to do in your spare time?”, “What are some of 
your weaknesses?”).  The actor was a 21-year-old, White-appearing woman of Hispanic 
ethnicity. Videos ranged from four to eight minutes long. Longer videos were needed for 
conditions that displayed ADHD symptoms so that symptoms such as excessive talking and 
distracted thinking could be adequately portrayed. A measure of perceived video length 
found that participants judged the videos to be of similar relative length across the 
conditions, F(3, 88) = 2.33, p = 0.08. In addition, participants were asked their level of 
attraction to the actor (“to what extent were you physically attracted to the actor?”), 
measured on an 11-point Likert scale from 0 (not at all) to 10 (very much).  
The video vignettes portrayed the actor as either (a) having normative behavior and 
not mentioning PSMU (control), (b) normative behavior and mentioning PSMU of Adderall 
(medication only, or MO), behavioral symptoms of ADHD but not mentioning PSMU 
(symptoms only, or SO), or behavioral symptoms of ADHD and mentioning PSMU of 
Adderall (SAM). Videos were briefly described to participants as impromptu interviews; 
participants were not told that the videos varied in portrayal of ADHD-related behaviors.  
The videos of those with behavioral symptoms (SO and SAM) depicted enough 
behavioral ADHD symptoms to meet the DSM-5 criteria for clinical diagnosis of the 
Combined presentation. Specifically, there were five symptoms of inattention and five 
symptoms of hyperactivity/impulsivity displayed. Inattentive symptoms were as follows: 
difficulty sustaining attention, not seeming to listen when directly addressed, difficulty with 
organization, frequently losing things, and being easily distracted by extraneous stimuli. 
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Hyperactive/impulsive symptoms were: fidgeting and squirming, leaving the seat that the 
person was expected to remain in, feelings of restlessness, acting as if being driven by a 
motor, and excessive talking. In addition, the actor in the SO and SAM videos made it known 
that she experienced her symptoms before the age of 12, the symptoms were present and 
impairing in multiple contexts, and that the only disorder the symptoms were attributed to 
was ADHD.  
The scripts of the videos were evaluated for accuracy in portrayal of these symptoms 
by four licensed psychologists who specialize in assessment and treatment of college students 
with ADHD. The responses to each question were filmed independently and edited together 
as a series of clips. This was done to ensure that the videos displayed behavior exactly the 
same way when indicated (e.g., SO and SAM responses that did not involve medication use). 
The only differences between videos that displayed the same behavior (i.e., [a] control and 
MO, [b] SO and SAM) was the inclusion of two mentions of prescribed use of Adderall. 
Specifically, in the MO video the actor mentioned that she had taken it, but in the SAM video 
the actor mentioned forgetting to take it that day. 
Desire for Affiliation (DFA). DFA was measured with three questions that 
immediately followed the video. The questions measured how likely the participant would be 
to affiliate with the portrayed individual in three contexts: as an employee (Imagine you are 
an employer looking to hire for an entry-level office job that requires both collaboration and 
independent projects. How likely would you be to hire this person?), as a roommate 
(Imagine you are looking for a roommate. Please disregard gender preference and focus on 
personality. How likely would you be to agree to live with this person?), and as a friend 
(Imagine you have just met this person. How likely would you be to become friends with this 
person?). Responses were made on an 11-point Likert scale that ranged from 0 (not at all 
ADHD MEDICATION AND SYMPTOM PERCEPTION 
17 
likely) to 10 (highly likely). Satisfactory internal consistency was noted between the three 
questions (Cronbach’s alpha, a = 0.76); as such, for efficiency and to minimize the chance of 
type I error, these were combined into one DFA index that reflects the mean score across the 
three items. This measure was created by the researcher specifically for this study in order to 
examine different dimensions of first impressions. Selecting to engage in an ongoing 
affiliation with someone (i.e., coworker, roommate, friend) may illustrate a different and 
more meaningful type of judgment than simply deciding whether one “likes” another.  
Degree of Liking (DOL). The independent variable of DOL was measured with the 
Interpersonal Liking Measure-6, created by Veskler & Eden (2017). The original measure 
was shortened by one item regarding enjoying interactions with the person in the past. The 
five remaining items assessed how much the participant liked the portrayed individual, 
asking participants to rate their agreement to statements on an 11-point Likert scale from 0 
(strongly disagree) to 10 (strongly agree; adapted from the original 9-point scale). The 
statements included measures of admiration (There are aspects of this person’s personality 
that I admire and I think that this person exhibits good judgment), similarity (I think that this 
person and I may have a lot in common), and desire for future interaction (I would like to get 
to know this person better and I think that future interactions with this person would be 
pleasurable). Internal reliability of the scale was good (a = 0.83). 
Treatment Acceptability Questionnaire. The Medication Treatment subscale of the 
Treatment Acceptability Questionnaire (TAQ; Kendall & Power, 2005) was used to assess 
pre-existing stigma against PSMU.  The eight-items concerned the participant’s opinions on 
the acceptability of PSMU to treat ADHD, specifically. Participants indicated their 
agreement to statements on the same 11-point Likert scale as described for the DFA (adapted 
from the original 6-point scale). Statements included judgments of the effectiveness of 
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medication (e.g., This treatment should be effective in changing someone with ADHD’s 
behavior), the necessity of the medication (e.g., ADHD-related problems are troublesome 
enough to justify the use of this treatment), as well as their personal support of its usage (e.g., 
I would be willing to use this treatment if I had ADHD and I like or support this treatment). 
The measure was adapted from the original to change the words “my child” to “a person with 
ADHD” for relevance. The internal reliability of the measure was good (a = 0.89). 
ADHD Knowledge Quiz. The ADHD Knowledge Quiz (KQ; Bramham et al., 2009) 
was used to assess the level of knowledge that participants had about ADHD. The quiz 
consists of 20 true/false general knowledge questions concerning etiology (e.g., ADHD is a 
disorder present from childhood and Whether you have ADHD depends on how you were 
brought up), behavior and symptoms (e.g., People with ADHD have difficulties 
concentrating and People with ADHD prefer short-term rewards over long-term rewards), 
assessments of value (e.g., ADHD is a problem of motivation and People with ADHD never 
fulfill their potential), as well as demographics (e.g., More females than males have ADHD). 
Neither the PsycTESTS record nor the original study provided the answer key the researchers 
used, and no response was received from the creators when the answer key was requested. 
Therefore, an answer key was created and reviewed by five licensed psychologists who 
specialize in assessment and treatment of ADHD with substantial clinical exposure to college 
student clients. Despite this precaution, unfortunately, internal consistency was poor for this 
measure (a = 0.22).  
Demographics. General demographic information (e.g., gender, age, sexual 
orientation, ethnicity) was collected on a questionnaire form (e.g., sex, gender, sexual 
orientation, age, ethnicity). In addition, the participant’s prior exposure to ADHD was 
measured by asking whether (a) the participant, (b) someone in their family, or (c) a friend 
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had been clinically diagnosed with ADHD (or another psychological disorder). They were 
also asked whether they suspected that they had ADHD (or another psychological disorder) 
without having a clinical diagnosis. The personal clinical diagnosis and self-suspected 
diagnosis were combined into one variable for analysis (0 = no, 1 = yes), as were the friends 
and family questions (0 = no, 1 = yes). 
Procedure 
Participants first completed a consent procedure, during which they were told that the 
goal was to measure perceptions of behavior when examined from different points of view. 
The goal of examining ADHD stigma was not disclosed in order to avoid biased responses to 
the video-related measures. Participants then watched one of the four videos (described 
above), which was selected via random assignment. Participants then completed the 
measures in a standardized order: measures of DFA, measure of DOL, Treatment 
Acceptability Questionnaire, Knowledge Quiz, and finally demographics. Upon completion, 
the researcher debriefed the participant by explaining the aspect of the study examining 
ADHD-related stigma. 
Results 
Preliminary Analyses 
 In order to see if there were personal characteristics such as pre-existing knowledge 
of ADHD that relate to and possibly influence the dependent variables, Pearson correlational 
analyses were conducted between (a) the Knowledge Quiz total score, (b) Treatment 
Acceptability Questionnaire total score, and (c) level of physical attraction the viewer felt for 
the actor and DFA and DOL scores. Similarly, Spearman correlational analyses were 
conducted to determine whether (a) gender, (b) sexual orientation, or (c) having close friends 
and/or family who are diagnosed with ADHD related meaningfully with DFA and DOL. No 
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statistically significant correlations were detected in any of these analyses (p > .06). Given 
this, none of these variables were included as covariates in the subsequent ANOVAs. 
Primary Analyses 
Analyses of desire for affiliation across groups. A one-way analysis of variance 
(ANOVA) was conducted to compare the effect of ADHD behavior and/or medication 
endorsement by the video target on participant’s DFA in the control, MO, SO, and SAM 
conditions. This analysis was found to be statistically significant, F(3, 88) = 11.13, p < .001. 
Post-hoc comparisons using Tukey tests indicated that the mean DFA scores for the control 
(M = 6.87, SD = 1.79) and MO (M = 6.52, SD = 1.15) targets differed significantly from the 
SO (M = 5.16, SD = 1.62) and SAM (M = 4.59, SD = 1.60) targets. No other statistically 
significant differences on DFA were detected across groups. Calculations of Cohen’s d 
values showed a large effect for all significant differences (see Tables 2 and 3 for more 
detail).  
 Analyses of degree of liking across groups. A one-way analysis of variance 
(ANOVA) was conducted to compare DOL score across the video conditions. This result was 
statistically significant, F(3, 88) = 8.80, p < .001. Post-hoc comparisons using Tukey tests 
indicated that the control target (M = 6.80, SD = 1.63) was preferred to the SO (M = 5.22, SD 
= 1.29) and SAM targets (M = 4.81, SD = 1.56), as measured by DOL. In addition, the MO 
target (M = 6.18, SD = 1.35) was also significantly better-liked than the SAM model. No 
other statistically significant differences on DOL were detected across groups. Examinations 
of Cohen’s d showed a large effect for all significant differences (see Tables 2 and 3). 
Discussion 
 This study aimed to investigate whether negative perceptions of ADHD were 
influenced more by the person using stimulant medication (i.e., Adderall) to treat the disorder 
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or by the observation of core symptoms themselves. Specifically, it was anticipated that 
either would result in negative perceptions, that symptoms would be more influential than 
medication usage, and that the stigma would be strongest when both were present. The data 
support that visible ADHD symptoms are associated with negative social stigma, both in 
terms of a desire to affiliate with the observed individual and how much the individual was 
liked. It was not clearly supported that stimulant medication usage had the same effect. Thus, 
it can be concluded that the symptoms of ADHD are more influential than being treated with 
stimulants for ADHD when considering negative perceptions against the disorder. More 
detailed discussion of individual hypotheses follows, as well as analysis of study limitations 
and suggestions for further research. 
Hypothesis One: ADHD Behavior will be Perceived Negatively versus non-ADHD 
Behavior  
 The data evidenced that depictions of ADHD behavior were perceived less positively 
than depictions of normative behavior. In terms of DFA, the control and MO conditions were 
rated higher than both the SO and SAM conditions. The same is largely true for DOL as well, 
as both the control and MO conditions were rated higher than the SAM condition, and 
control was rated better than SO. A discrepancy between the two measures was seen here, as 
DOL indicated that MO and SO were liked equally. However, analysis of Cohen’s d showed 
that the effect size between the two conditions was approaching large (d = 0.73). This 
suggests that perhaps the lack of difference between the two conditions could be due to a 
small sample size without enough power to show significant differences. 
 This evidence aligns with the current literature regarding perceptions of ADHD. Canu 
et al. (2008) noted a desire for social distance among those who read about individuals with 
ADHD, resulting in reluctance to form social bonds with affected individuals. This closely 
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aligns with the current data, as participants who directly observed ADHD behavior 
consistently indicated less of a desire to affiliate with the person than those who did not. 
ADHD behaviors seem to result in a reduced chance that one will want to affiliate or form 
any type of bond with the affected individual. Further, research regarding perception of 
ADHD points to disordered behavior leading to more negative mood in the observer (Paulson 
et al., 2005). This negative mood could result in liking the observed person less, leading to 
the lower scores seen in the extent to which the observer likes the depicted person. 
Hypothesis Two: PSMU will be Perceived Negatively versus no PMSU 
 The data did not support that PSMU is perceived less positively than a lack thereof. In 
both DFA and DOL, there were no significant differences in ratings of conditions that 
mentioned medication and those that did not in the context of the same behavior. That is, 
there were no significant differences in ratings between conditions that did not depict ADHD 
behavior (control and MO), nor in those that did (SO and SAM). For both DFA and DOL, 
mentioning medication did not lower ratings significantly when comparing MO to control 
and SAM to SO.  
 This result is somewhat surprising since previous literature indicates that those who 
use psychiatric medications like antidepressants tend to be the targets of stigma (Casteldelli-
Maia et al., 2011). However, perhaps the population sampled herein may might be associated 
with fewer negative perceptions of PSMU. Specifically, there is a robust body of research 
that indicates stimulant medications are frequently abused in college populations by those 
that do not have ADHD. Rates vary, but research indicates that anywhere from 8.1% to as 
many as 43% of college students without ADHD have reported illicitly using stimulant 
medications to enhance academic performance, with average rates appearing to be 10-20% 
(McCabe, Teter, & Boyd, 2006; Advokat, Guidry, & Martino, 2008; Hall et al., 2005). Rates 
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of illicit stimulant usage have increased in the past years (Judson & Langdon, 2009), and 
even more than a decade ago a large proportion of students (approximately 44%) reported 
knowing someone who used stimulant medications without a prescription (Hall et al., 2005). 
In other words, there may be a kind of positive halo around stimulant medications because 
they are thought by college students to have a bolstering effect on GPA. This may possibly 
be associated with the greater acceptance of stimulant medication usage in this population 
(Judson & Langdon, 2009), despite its commonly known application in the treatment of 
individuals with ADHD.  
Hypothesis Three: Depictions of Symptoms Alone will be Perceived More Negatively 
than Depictions of Medication Alone 
 The data mostly confirmed this hypothesis. In terms of DFA, the condition that only 
mentioned medication (MO) was rated more positively than the condition that only displayed 
symptoms (SO). In terms of DOL, the ratings were not statistically significant. As previously 
mentioned, however, it is possible that the sample size did not contain enough power to 
indicate a significant difference, despite an effect size between the two groups that 
approaches the large range (see Table 3).  
 Considering the work of Masuch et al. (2018), it might be expected that symptoms 
alone would be more impactful to DOL than the mention of prescription medication use. The 
core symptoms of ADHD may appear to others as dislikable aspects of personality, such as 
irresponsibility and rudeness. Beyond stigma relating to the knowledge that one has a mental 
disorder, a person may be perceived as flawed intrinsically rather than struggling with 
symptoms. This may also contribute to the difference between MO and SO in terms of DFA: 
the person showing ADHD symptoms not only could be stigmatized due to their label, but 
also because their expression of symptoms leads the person to believe that they would not 
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make a desirable employee, roommate, or friend. Since these areas of affiliation require 
continued interaction, an observer may want to distance themselves from the person to 
decrease their chances of being negatively affected by the traits the person exhibits. 
Like in hypothesis two, this finding is perhaps also understandable in light of how 
common misuse of ADHD medication is among college students (Advokat et al., 2008). In a 
context in which ADHD medication is often used beyond its intended medical purpose there 
may be a neutral or even positive perception, as medication is used by non-stigmatized 
groups as well. 
Hypothesis Four: Depictions Symptoms plus PSMU will be Most Negatively Perceived 
 The data again provides partial support of this hypothesis. In both DFA and DOL, the 
control and MO conditions were rated higher than SAM. However, analyses of both 
conditions showed that ratings for the SO condition were not significantly different from the 
SAM conditions. It may be of note, thought that for DFA the effect size between SO and 
SAM was approaching moderate, again pointing to the possibility that the small the sample 
size may mask a real difference between these groups (see Table 3). 
 These results were contrary to expectations and the existent literature. It was 
anticipated that a combination of stimulant medication usage and visible ADHD symptoms 
would combine to create increased stigma in the perceiver. Despite the lack of research 
regarding ADHD medication stigma, the certain knowledge that one is diagnosed with 
ADHD (due to stimulant prescription) was expected to worsen perceptions of the afflicted 
individual. Canu et al. (2008) found that even without the presence of visible symptoms, a 
label of having ADHD contributed to negative perceptions. Though the effect sizes in the 
study were medium, this still points to the idea that simply knowing one has ADHD could 
results in a somewhat less favorable view of that person, even when the appraiser does not 
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see their symptoms. In the videos, it was indicated that the actor was taking prescribed 
Adderall for treatment of their ADHD, effectively labeling them as having the disorder and 
demonstrating its effects through behavior. In the SO condition video, the actor mentioned 
that she had ADHD. However, it was at the very end of the video and was not discussed in 
great depth. It was expected that mentioning PSMU three times in the SAM condition video 
would increase the impact of the label, as the medication was mentioned in the first clip, 
reiterated in the middle, and the diagnosis was confirmed and the PSMU reinforced at the 
end. 
 Considering that the normative behavior groups (control and MO) were generally 
liked more and considered more desirable as potential associates, it may be that the mention 
of medication or label of having ADHD is not as significant contributor to negative 
perceptions or stigma as was anticipated, at least if ADHD symptoms are visible and obvious. 
In other words, a label may have some negative effects for stigma, but actually seeing the 
offputting symptoms of ADHD may trump any such effect. This result points to symptoms as 
the most important determinant of stigma, with medication mention playing a much less 
influential role. 
Limitations and Future Directions 
 There were several limitations of note in this research. Perhaps most significantly, the 
sample size was not large enough to show differences between groups that may have been 
present. With only 23 people in each condition, there was not enough statistical power to 
reveal the significance of several effects that approached moderate or even large size (see 
Table 3). In both DFA and DOL, the effect size of the differences between the SO and SAM 
conditions approached moderate, but the post-hoc Tukey tests did not have statistically 
significant results. This may help explain the lack of support for the fourth hypothesis – 
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perhaps if the sample had been larger, the difference between perception of symptoms only 
versus perception of reinforced labels, medication, and symptoms would be more clear. This 
is also seen in DOL, where the effect size between the MO and SO groups approached large 
but showed no significant differences. Again, were the sample size larger, it is expected that 
there would be a significant difference between the two. In this case, there would be greater 
support for the second hypothesis, indicating that symptoms alone are more influential than 
medication alone, as was seen in DFA. In everyday life these effects could be observable by 
the average person, but the sample in this case was not large enough to support the trends. 
Another limiting factor was that the Knowledge Quiz used to assess the participant’s 
level of familiarity with ADHD concepts, was not adequately reliable, despite four doctorate-
level ADHD researchers concurring on an answer key. As reliability is a necessary 
component of validity, the use of this measure as a true indicator of knowledge about ADHD 
is suspect. Several of the questions had debatable answers, and scores achieved may not have 
accurately reflected the participant’s level of understanding regarding ADHD. However, this 
measure was adapted from the published literature, with a number of studies having relied on 
it. While it was not a robust measure, its lack of association with DFA and DOL may not 
entirely be a fluke here. In fact, preliminary analyses found no influence of having a close 
friend or relative with the disorder on ratings of DOL or DFA, which would result in greater 
knowledge about ADHD. 
 There were other measures-related issues, including the “attractiveness” question 
used as a possible control for biased opinions of the actor due to physical attraction. The 
question asked how attracted the participant was to the actor, whereas asking how attractive 
the actor was may have yielded a better index. People who are judged as more attractive tend 
to be viewed in a better light. Further, those judged more attractive tend to be considered 
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more normative, which has been found to have a greater level of desirability than non-
normative personalities or behaviors (Lorenzo, Biesanz, & Human, 2010). This occurs 
regardless of sexual orientation and indicates that one may consider someone to be less 
“different,” easier to like, and a more desirable person with which to affiliate, even if they are 
not sexually attracted to them. Future research may benefit from examining how perceptions 
of how generally attractive a target is could influence stigma, regardless of whether a person 
feels a personal (i.e., sexual) attraction.  
 The sample could also be considered limited, as the majority of participants were 
white, heterosexual, and female (see Table 1). Considering that women are typically more 
supportive of professional treatment for mental illness (Holzinger, Floris, Schomerus, & 
Carta, 2011), stigmatic beliefs may not have been as present in this study as it would be for a 
more balanced sample, particularly in regard to medication acceptability. In addition, the lack 
of diversity in the sample indicates that these results may not be generalizable to a larger 
population. Further, as mentioned above, there was a lack of satisfactory statistical power in 
the sample, which limited ability to detect some possibly-real effects. Future research would 
benefit from a larger, more varied population and a deeper investigation into the gender 
differences that could influence perceptions of mental illness.  
 In the same vein, future research could gain from investigating the impact of gender 
and race on perceptions of ADHD. The current study employs a White-appearing actress that 
generally acts similarly to mainstream women of her age. The same actress was used across 
video types to ensure that gender or race was not a confounding variable. Different stigmatic 
judgments might be made by research participants if the observed individual is a man, or 
non-gender conforming, or of a minority ethnicity. Future research would do well to explore 
these possibilities. 
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 The current study attempted to depict a wide range of potential ADHD symptoms by 
presenting the actor as having ADHD of the Combined presentation type. While this yields 
results that illustrate stigma relating to ADHD symptoms in general, it is worth investigating 
how different clusters of symptoms may have an impact on perception. Future research in 
this area could thereby investigate the differences in perception between observation targets 
that have the predominantly IA and HI presentations of ADHD, as well as the Combined 
presentation. 
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Table 1. 
Means (Standard Deviations): Descriptive Statistics 
 
Sex 
     Male 
     Female 
 
17.4% (n = 16) 
82.6% (n = 76) 
Age 19.61 (1.56) 
Ethnicity 
     White/Caucasian 
     Black/African American 
     Hispanic/Latino 
 
90.2% (n = 83) 
6.5% (n = 6) 
3.3% (n = 3) 
Sexual Orientation 
     Heterosexual 
     Homosexual 
     Multiple-gender attraction 
 
91.3% (n = 84) 
3.3% (n = 3) 
5.4% (n = 5) 
Relatedness to ADHD 
     Others 
          Close friend/family with ADHD 
     Self 
          Clinical diagnosis 
          Suspected diagnosis 
 
 
71.6% (n = 66) 
 
10.9% (n = 10) 
3.3% (n = 3) 
Knowledge Quiz  14.73 (1.82) 
Treatment Acceptability Questionnaire 52.09 (12.02) 
Note. Knowledge Quiz score given in terms of average total correct out of 20. Treatment 
Acceptability Questionnaire score given as average total out of 80. 
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Table 2. 
Means (Standard Deviations), ANOVA Results, and Post-Hoc Analysis Results for Dependent 
Variables for Desire for Affiliation and Degree of Liking 
 
 Descriptive Statistics Analysis Results 
Variable Video F Tukey 1 2 3 4 
DFA 6.87 (1.79) 
 
6.52 
(1.15) 
 
 
5.16 
(1.62) 
 
 
4.59 
(1.60) 
 
11.13 (1 = 2) > (3 = 4) 
DOL 
 
6.80 
(1.63) 
 
6.18 
(1.35) 
5.22 
(1.29) 
4.81 
(1.56) 8.80 
(1 = 2) 
(1 > 3 & 4) 
(2 = 3) 
(2 > 4) 
(3 = 4) 
Note. For variables: 1 = control video condition, 2 = medication mention only video 
condition, 3 = symptom display only video condition, 4 = symptom display and medication 
mention condition. DFA = Desire for Affiliation, DOL = Degree of Liking. Both F values 
reached statistical significance (i.e., both were p < 0.001).  
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Table 3.  
Measures of Effect Sizes Between Groups for Desire for Affiliation (DFA) and Degree of 
Liking (DOL) as Measured by Cohen’s d
 
DFA  DOL 
Video 2 3 4  Video 2 3 4 
1 0.24 1.0 1.35  1 0.42 1.08 1.25 
2  0.24 1.0  2  0.73 0.94 
3   0.35  3   0.29 
ADHD MEDICATION AND SYMPTOM PERCEPTION 
38 
Appendix A 
IRB Approval Letter 
To: Mia Cave Psychology CAMPUS EMAIL  
From: Dr. Andrew Shanely, IRB Chairperson 
Date: December 19, 2018 
RE: Notice of IRB Approval by Expedited Review (under 45 CFR 46.110)  
STUDY #: 19-0134 
STUDY TITLE: Is it the Medication or the Symptoms? Examining Perceptions of ADHD in 
College Students. 
Submission Type: Initial 
Expedited Category: (7) Research on Group Characteristics or Behavior, or Surveys, 
Interviews, etc. Approval Date: 12/19/2018 
Expiration Date of Approval: 12/18/2019  
The Institutional Review Board (IRB) approved this study for the period indicated above. The 
IRB found that the research procedures meet the expedited category cited above. IRB approval is 
limited to the activities described in the IRB approved materials, and extends to the performance 
of the described activities in the sites identified in the IRB application. In accordance with this 
approval, IRB findings and approval conditions for the conduct of this research are listed below.  
Study Regulatory and other findings:  
The IRB determined that this study involves minimal risk to participants.  
All approved documents for this study, including consent forms, can be accessed by logging into 
IRBIS. Use the following directions to access approved study documents.  
1. Log into IRBIS 
2. Click "Home" on the top toolbar 
3. Click "My Studies" under the heading "All My Studies" 4. Click on the IRB number for the 
study you wish to access 5. Click on the reference ID for your submission 
6. Click "Attachments" on the left-hand side toolbar 
7. Click on the appropriate documents you wish to download  
Approval Conditions:  
Appalachian State University Policies: All individuals engaged in research with human 
participants are responsible for compliance with the University policies and procedures, and IRB 
determinations.  
ADHD MEDICATION AND SYMPTOM PERCEPTION 
39 
Principal Investigator Responsibilities: The PI should review the IRB's list of PI responsibilities. 
The Principal Investigator (PI), or Faculty Advisor if the PI is a student, is ultimately responsible 
for ensuring the protection of research participants; conducting sound ethical research that 
complies with federal regulations, University policy and procedures; and maintaining study 
records.  
Modifications and Addendums: IRB approval must be sought and obtained for any proposed 
modification or addendum (e.g., a change in procedure, personnel, study location, study 
instruments) to the IRB approved protocol, and informed consent form before changes may be 
implemented, unless changes are necessary to eliminate apparent immediate hazards to 
participants. Changes to eliminate apparent immediate hazards must be reported promptly to the 
IRB.  
Approval Expiration and Continuing Review: The PI is responsible for requesting continuing 
review in a timely manner and receiving continuing approval for the duration of the research 
with human participants. Lapses in approval should be avoided to protect the welfare of enrolled 
participants. If approval expires, all research activities with human participants must cease.  
Prompt Reporting of Events: Unanticipated Problems involving risks to participants or others; 
serious or continuing noncompliance with IRB requirements and determinations; and suspension 
or termination of IRB approval by an external entity, must be promptly reported to the IRB.  
Closing a study: When research procedures with human subjects are completed, please log into 
our system at https://appstate.myresearchonline.org/irb/index_auth.cfm and complete the 
Request for Closure of IRB review form.  
Websites:  
1. PI responsibilities:  
http://researchprotections.appstate.edu/sites/researchprotections.appstate.edu/files/PI%20Respon
sibilities.pdf  
2. IRB forms: http://researchprotections.appstate.edu/human-subjects/irb-forms  
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Appendix B 
Informed Consent 
Informed Consent 
Social Appraisals in Different Contexts 
 
What is this study about? 
This study aims to investigate how people perceive and appraise others when asked to 
view them from various contexts. It explores how the same words and actions may be evaluated 
differently when the situation or point of view from which they are being observed is changed, 
e.g. during a job interview vs. a friendly chat. 
 
What will I be asked to do? 
You will be asked to watch a short video of a person answering general questions about 
themselves. You will then fill out questionnaires that examine: your appraisals of the person, 
your knowledge, opinions, and perceptions of certain topics, personality information about 
yourself, and your demographics and history.  
 
Is there any sensitive information required? How will my private information be kept 
confidential? 
The only sensitive information you will be asked to provide is your name and a small 
amount of medical history.  
Your name will only be used to sign up and get credit through SONA, in the use of a 
study reminder email the day before your time slot, and on this informed consent form. The only 
physical record of your name, the informed consent, will be kept separately from the rest of your 
data and responses. Both will be kept in locked filing cabinets. All data entered into the online 
database used for analysis and storage will be tied only to your participant number.  
Your medical history is self-report only, and will not have any identifiers tied to it. No 
information given will be able to be traced to you, nor can it incriminate you in any way. 
 
Do I meet the requirements for participation? 
 If you are 18 or older, an undergraduate student, and are participating through SONA, 
you meet basic requirements. Since you will be watching a video that includes audit, having a 
physical disability that would severely interfere with the study administration or data collected 
(e.g. severe visual or auditory impairment) may prevent you from being able to participate. 
 
How long will this study take? 
 The time slot is for one half hour (30 minutes). It is typically expected that the study will 
take less than the allotted time, but this cannot be guaranteed. 
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What possible harms or discomforts may I experience during this study? 
 No harms nor discomforts (physical, mental, or emotional) greater than those experienced 
in everyday life are expected to occur. If any should arise, please inform the research assistant. 
 
What possible personal benefits are there to this study? 
You will not be paid for your participation in this study.  However, you can earn 1 ELC 
credit for your participation.  There are other research options and non-research options for 
obtaining extra credit or ELC's.  One non-research option to receive 1 ELC is to read an article 
and write a 1-2 page paper summarizing the article and your reaction to the article.  More 
information about this option can be found at: psych.appstate.edu/research.  You may also wish 
to consult your professor to see if other non-research options are available. 
 
Whom should I contact with any questions I may have? 
 The research assistant will answer any remaining questions to the best of their knowledge 
following the completion of study administration. Any other questions can be directed to the 
Principal Investigator, Jamie Cave, at cavemj@appstate.edu. You may also contact the Faculty 
Advisor, Dr. Will Canu, at 828-262-2272 extension 412.  
Questions regarding the protection of human subjects may be addressed to the IRB 
Administrator, Research Protections, Appalachian State University, Boone, NC 28608 (828) 
262-2692, irb@appstate.edu 
 
Do I have to participate? 
 No! Your participation is entirely voluntary. You may cease to participate at any time, 
even if you have signed the Informed Consent form. Aside from not receiving full (if any) ELC 
credit, there will be no penalty and you will not lose any rights you would normally have.  
 
  
 
________________________________ 
Printed Name 
 
________________________________ 
Signature 
 
________________________________ 
Date 
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Appendix C 
Debriefing 
Social Appraisals in Different Contexts 
Otherwise known as: 
Is it the Medication or the Symptoms? Examining Perceptions of ADHD in College Students. 
 
Thank you for participating in this study!  This form provides an explanation of what the study 
aimed to examine as well as why minor deception has been used. Please feel free to ask any 
questions or to comment on any aspect of the study. 
 
You have been told that this study sought to examine how people appraise others differently 
when asked to view the target person from different points of view or in different contexts. 
While this is true, minor deception was used to conceal the more specific aim of the study. 
 
In actuality, we were interested in the perceptions and stigma regarding ADHD in college 
students. More specifically, how the perception and/or stigma of ADHD is different when the 
observer is informed that the participant takes prescribed medication for ADHD (and 
subsequently knows that the person has been diagnosed) from when the observer only sees 
common symptoms of ADHD. Participants have all seen a video with the same actor and general 
responses to the questions, but the actor behaves differently in different conditions. Some 
participants saw a video that showed no symptoms of ADHD and did not mention medication 
usage, some saw one that only mentions medication usage (no symptoms), some saw one that 
only displays symptoms (no mention of medication), and some saw one that involved both. All 
participants completed the same questionnaire measures. 
 
To protect the integrity of the research, and avoid demand characteristics and influenced 
responses, it was necessary to withhold this information. 
 
As you know, your participation in this study is voluntary. If you so wish, you may withdraw 
after reading this debriefing form, at which point all records of your participation will be 
destroyed. You will not be penalized if you withdraw. 
 
As you are likely not the last participant sampled, it is important that you do NOT discuss this 
study, particularly its true aims, with anyone. This includes verbally, over text, email, etc. This 
may bias future participants’ responses and may severely compromise the accuracy of the data 
we collect. We hope you will support our research by keeping your knowledge of this study 
confidential. 
 
Please return this copy of the debriefing form to the research assistant. A copy of the Informed 
Consent may be kept. 
 
You may ask the research assistant any questions you may have or contact the Principal 
Investigator, Jamie Cave, at cavemj@appstate.edu. You may also contact the Faculty Advisor, 
Dr. Will Canu, at 828-262-2722, extension 412. 
 
Thank you again for your participation! The study has now ended.   
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Appendix D 
Measures 
Appraisals of Observed Individual 
Situation 1: Imagine you are an employer looking to hire for an entry-level office job that 
requires both collaboration and independent projects.  
 
1. Would you consider hiring this person? (Circle one) 
a. Yes  
b. No 
2. How likely would you be to hire this person? (Circle one) 
Not at 
all likely 
         Highly 
likely 
0 1 2 3 4 5 6 7 8 9 10 
 
Situation 2: Imagine you are looking for a roommate. Please disregard gender preference and 
focus on personality.  
 
1. Would you consider living with this person? (Circle one) 
a. Yes  
b. No 
2. How likely would you be to agree to live with this person? (Circle one) 
Not at 
all likely 
         Highly 
likely 
0 1 2 3 4 5 6 7 8 9 10 
 
Situation 3: Imagine you have just met this person. 
1. Would you consider becoming friends with this person? (Circle one) 
a. Yes  
b. No 
2. How likely would you be to become friends with this person? (Circle one) 
Not at 
all likely 
         Highly 
likely 
0 1 2 3 4 5 6 7 8 9 10 
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Evaluation of Video 
1. How long did the video seem to you? (Circle one) 
Too 
short 
         Too 
long 
0 1 2 3 4 5 6 7 8 9 10 
           
2. To what extent were you physically attracted to the actor? (Circle one) 
Not at 
all 
         Very 
much 
0 1 2 3 4 5 6 7 8 9 10 
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ILM 
Please circle the number that corresponds to how much you agree or disagree. 
1. I think that this person and I may have a lot in common.  
Strongly 
disagree 
         Strongly 
Agree 
0 1 2 3 4 5 6 7 8 9 10 
2. There are aspects of this person’s personality that I admire.  
Strongly 
disagree 
         Strongly 
Agree 
0 1 2 3 4 5 6 7 8 9 10 
3. I think that this person exhibits good judgment.  
Strongly 
disagree 
         Strongly 
Agree 
0 1 2 3 4 5 6 7 8 9 10 
4. I think that future interactions with this person would be pleasurable.  
Strongly 
disagree 
         Strongly 
Agree 
0 1 2 3 4 5 6 7 8 9 10 
5. I would like to get to know this person better.  
Strongly 
disagree 
         Strongly 
Agree 
0 1 2 3 4 5 6 7 8 9 10 
 
  
ADHD MEDICATION AND SYMPTOM PERCEPTION 
46 
TAQ 
This measure requires you to think about the usage of prescribed medication to treat ADHD. 
Please write the number on the line that best indicates the extent of your agreement or 
disagreement, as per below. 
 
Strongly 
disagree 
         Strongly 
Agree 
0 1 2 3 4 5 6 7 8 9 10 
 
1. _____ This is an acceptable treatment for someone with ADHD’s behavior. 
2. _____ This treatment should be effective in changing someone with ADHD’s behavior.  
3. _____ ADHD-related problems are troublesome enough to justify the use of this treatment. 
4. _____ I would be willing to use this treatment if I had ADHD.  
5. _____ This treatment would not have bad side effects for those with ADHD. 
6. _____ I like or support this treatment. 
7. _____ This treatment is a good way to handle the problems faced by those with ADHD.  
8. _____ Overall, this treatment would help someone with ADHD.  
 
  
ADHD MEDICATION AND SYMPTOM PERCEPTION 
47 
Knowledge Quiz 
Please circle the appropriate letter according to whether you think the following 20 statements 
are true or false. Please answer according to your knowledge of the disorder in general, rather 
than relating the questions to yourself.  
 
1. ADHD is a disorder present from childhood  T   F 
2. ADHD is contagious . T   F 
3. People with ADHD find it difficult to follow rules. T   F 
4. ADHD symptoms can be treated with medication. T   F 
5. People with ADHD never fulfill their potential. T   F 
6. People with ADHD are distractible. T   F 
7. People with ADHD have difficulties concentrating. T   F 
8. People “grow out” of ADHD but the rate varies from person to person. T   F 
9. People with ADHD are less intelligent than the normal population. T   F 
10. Whether you have ADHD depends on how you were brought up. T   F 
11. More females than males have ADHD.  T   F 
12. People with ADHD prefer short-term rewards over long-term rewards. T   F 
13. People with ADHD have difficulties with self-restraint. T   F 
14. ADHD is a lifelong condition. T   F 
15. People with ADHD become bored more easily than other people.  T   F 
16. People with ADHD are likely to have additional psychological problems. T   F 
17. People with ADHD rarely get tired.  T   F 
18. ADHD is a problem of motivation. T   F 
19. People with ADHD find it difficult to organize themselves. T   F 
20. People with ADHD are slow to understand instructions. T   F 
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Demographics and Background Information 
 Please remember that all of the information you provide is strictly confidential. No 
information will be shared with anyone else, cannot incriminate you, and will be disposed of 
following the termination of the study. 
 
1. Age: ______ 
2. Gender (circle one):      
a. Male 
b. Female 
c. Nonbinary or non-gender conforming 
3. Sexual orientation (circle one): 
a. Heterosexual (“straight”)  
b. Bisexual, pansexual, or other multiple-gender attraction 
c. Gay or lesbian 
d. Asexual 
4. Ethnicity (circle one) 
a. American Indian/Alaska Native 
b. Asian 
c. Native Hawaiian or Other Pacific Islander 
d. Black or African American 
e. White or Caucasian/European American 
f. Hispanic/Latino 
g. Multiracial 
h. Unknown or other: _________ 
5. Have you been diagnosed with any psychological disorders or mental illness? If so, 
which ones? 
________________________________________________________________________
________________________________________________________________________ 
6. Do you suspect you may have other psychological disorders or mental illness? If so, 
which ones? 
________________________________________________________________________
________________________________________________________________________ 
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7. Do you have any family or friends with ADHD? Please note their relationship to you 
________________________________________________________________________
________________________________________________________________________ 
8. Do you have any family or friends with another psychological disorder? If so, which 
disorders? 
________________________________________________________________________
________________________________________________________________________ 
9. Are you prescribed medication to treat ADHD? If so, indicate type, dosage, and 
frequency of use. 
________________________________________________________________________
________________________________________________________________________ 
10. Do you use medication that treats ADHD for which you do not have a prescription? If so, 
indicate type, dosage, and frequency of use. 
________________________________________________________________________
________________________________________________________________________ 
11. What is your year in college? (circle one) 
a. Freshman 
b. Sophomore 
c. Junior 
d. Senior 
e. “Supersenior,” Fifth year, etc. 
12. What is your major/minor (or intended major/minor)? 
________________________________________________________________________ 
13. What type of environment were you raised in? 
a. Rural 
b. Suburban 
c. Urban 
14. What type of school did you attend? 
a. Public  
b. Private 
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15. What is your estimated cumulative college GPA?  
__________ 
16. What was your high school GPA? 
__________ 
 
 
 
 
 
 
 
